Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Caribou Biosciences (CRBU) Income from Continuing Operations (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Income from Continuing Operations for 6 consecutive years, with 29400000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Income from Continuing Operations rose 23.11% to 29400000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 154091000.0, a 6.71% increase, with the full-year FY2025 number at 148125000.0, up 0.66% from a year prior.
  • Income from Continuing Operations was 29400000.0 for Q3 2025 at Caribou Biosciences, up from 47578000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 13159000.0 in Q1 2021 to a low of 47578000.0 in Q2 2025.
  • A 5-year average of 29609722.22 and a median of 29989000.0 in 2022 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: plummeted 664.48% in 2021, then surged 44.86% in 2023.
  • Caribou Biosciences' Income from Continuing Operations stood at 18479000.0 in 2021, then crashed by 65.47% to 30578000.0 in 2022, then dropped by 22.45% to 37442000.0 in 2023, then decreased by 3.83% to 38875000.0 in 2024, then grew by 24.37% to 29400000.0 in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Income from Continuing Operations are 29400000.0 (Q3 2025), 47578000.0 (Q2 2025), and 38875000.0 (Q4 2024).